They highlight the role of the gut-kidney axis in the management and treatment of chronic kidney disease in dogs and cats.
Chronic kidney disease (CKD) in cats and dogs poses significant clinical problems, and new research highlights the critical role gut-kidney axis in its pathogenesis and treatment.
In this sense intestinal dysbiosischaracterized by changes in the composition and function of the intestinal microbiome, promotes microbial dysmetabolism of key nutrients, which causes accumulation of uremic toxins and changes in amino acid, bile acid, and fatty acid profiles. These changes, in turn, exacerbate renal dysfunction and systemic inflammation.
Recent research in veterinary medicine, especially in cats, supports the gut microbiome and metabolites derived from microbes such as new therapeutic targets.
Potential therapeutic strategies targeting the gut microbiome and microbial dysmetabolism, including dietary management, probioticsadsorbents and treatment of constipation, we offer promising areas of intervention to reset metabolic balance and preservation of kidney function.
In this regard, a scientific review published by researchers from Ohio and Oregon universities emphasizes microbial influence on kidney health and focuses on potential therapeutic strategies available to veterinarians to optimize the treatment of CKD in cats and dogs.
Among the review’s findings is that due to the complex interactions between the gut microbiome, microbial metabolites and kidney function, changes in the gut-kidney axis contribute to morbidity and progress chronic kidney disease.
“Although our understanding of the gut-kidney axis in veterinary medicine is evolving, recent studies highlight Parallels with data obtained in patients with CKDwhich underscores its clinical significance,” they point out.
Thus, they emphasize that in the future Targeting the gut as a therapeutic shows promise to reduce uremic toxin load and improve patient outcomes. “Strategies such as diet, probiotics, adsorbents, and treatment of constipation offer promising opportunities for intervention,” they say.
“Using knowledge of the gut-kidney axis, veterinarians can optimize management strategies and improve patient care to improve the quality of life of cats and dogs with CKD. Continued research in this area will further elucidate the complexities of this axis and pave the way for innovative approaches to the treatment of CKD,” the researchers conclude in the review.
Taking all this into account, supplementing with live bacteria can help balance dysbiosis. In this sense, veterinarians have at their disposal tools such as Prokanikare Plus from SpitA gastrointestinal stimulant Formulated from the gut bacteria of healthy dogswhich contains 3 strains of live bacteria lactobacilli of canine origin, making it a logical choice as a bacterial gastrointestinal stimulation for dogs.
Prokanikare Plus supports dog microbiota reducing the number of harmful bacteria and helping the animal’s own beneficial bacteria multiply. Ecuphar continues to develop its own line of microbiome-based products that focus on holistic care and support for healthy bacterial balance, while also providing innovative long-term solutions.
ACCESS TO ADDITIONAL INFORMATION